Median Technologies Announces Rebranding Of Ibiopsy®, Changes Name To Eyonis™

By Author: Arina Smith
Total Articles: 185
Comment this article

Median Technologies, a leading player in innovative imaging solutions, has embarked on a comprehensive rebranding initiative, unveiling a new identity for its iBiopsy® suite of software as medical devices (SaMD). The company has officially rebranded iBiopsy® to the new name Eyonis™, marking a significant milestone in Median's corporate trajectory and emphasizing its commitment to delivering cutting-edge SaMD to the radiology market.

The rebranding introduces a new logo, tagline, and visual identity for Eyonis™. The brand name itself is a fusion of "Eye" and "Onis," symbolizing a connection to visual imaging and power. The tagline, "Catching the Unseen," reflects Median's dedication to leveraging the power of medical images and artificial intelligence (AI) to reveal previously unseen insights, enabling better and earlier diagnosis of patients.

Thomas Bonnefont, COO and CCO of Eyonis™, highlighted the transformative journey from iBiopsy® to Eyonis™, emphasizing the etymology linked to vision, power, and efficacy. The rebranding builds on the foundation of excellence defined by iBiopsy® while positioning ...
... Eyonis™ as a renewed vision to redefine benchmarks of success in early cancer diagnosis.

Eyonis™'s brand visual identity was unveiled at the Radiological Society of North America (RSNA) 2023 Annual Meeting in Chicago, IL, USA. The company showcased its AI/ML tech-based suite of SaMD at booth #4465, Level 3 South Hall (AI showcase). Eyonis™ will serve as the commercial name for Median's SaMD portfolio in the US and Europe upon receiving the 510K clearance from the FDA and the CE marking in Europe.

The rebranding aligns with Median's commitment to advancing healthcare through innovative imaging solutions. The company leverages advanced AI technologies to enhance the accuracy of cancer diagnosis and treatment at early stages, providing insights into novel therapies. Median's iCRO solutions for medical image analysis in oncology trials and Eyonis™ contribute to bringing new treatments and enabling earlier and more accurate diagnoses.

Founded in 2002 and headquartered in Sophia-Antipolis, France, Median Technologies has received recognition as an "Innovative company" by the BPI and is listed on the Euronext Growth market (Paris) under the ticker ALMDT. The company is eligible for the French SME equity savings plan scheme (PEA-PME).

In summary, Median Technologies' rebranding initiative marks a strategic move to strengthen its position in the field of AI-powered medical imaging. Eyonis™ represents a renewed commitment to harnessing the potential of AI and medical images for improved healthcare outcomes, particularly in the early diagnosis of cancers.

https://www.techdogs.com/tech-news/business-wire/median-technologies-announces-rebranding-of-ibiopsy-changes-name-to-eyonis